The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study

Bibliographic Details
Main Authors: MS Sandoz, GW Keusch
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2004-08-01
Series:Swiss Medical Weekly
Subjects:
Online Access:https://www.smw.ch/index.php/smw/article/view/399
_version_ 1811193956653858816
author MS Sandoz
GW Keusch
author_facet MS Sandoz
GW Keusch
author_sort MS Sandoz
collection DOAJ
first_indexed 2024-04-12T00:18:08Z
format Article
id doaj.art-a8ef462e79dc46b6a9a84dc040f90602
institution Directory Open Access Journal
issn 1424-3997
language English
last_indexed 2024-04-12T00:18:08Z
publishDate 2004-08-01
publisher SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
record_format Article
series Swiss Medical Weekly
spelling doaj.art-a8ef462e79dc46b6a9a84dc040f906022022-12-22T03:55:47ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972004-08-01134313210.4414/smw.2004.10492The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL studyMS SandozGW Keuschhttps://www.smw.ch/index.php/smw/article/view/399SwitzerlandNephropathyDiabetescost effectivenessLosartan
spellingShingle MS Sandoz
GW Keusch
The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study
Swiss Medical Weekly
Switzerland
Nephropathy
Diabetes
cost effectiveness
Losartan
title The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study
title_full The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study
title_fullStr The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study
title_full_unstemmed The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study
title_short The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study
title_sort cost effectiveness of losartan in type 2 diabetics with nephropathy in switzerland an analysis of the renaal study
topic Switzerland
Nephropathy
Diabetes
cost effectiveness
Losartan
url https://www.smw.ch/index.php/smw/article/view/399
work_keys_str_mv AT mssandoz thecosteffectivenessoflosartanintype2diabeticswithnephropathyinswitzerlandananalysisoftherenaalstudy
AT gwkeusch thecosteffectivenessoflosartanintype2diabeticswithnephropathyinswitzerlandananalysisoftherenaalstudy
AT mssandoz costeffectivenessoflosartanintype2diabeticswithnephropathyinswitzerlandananalysisoftherenaalstudy
AT gwkeusch costeffectivenessoflosartanintype2diabeticswithnephropathyinswitzerlandananalysisoftherenaalstudy